Novo NordiskNVO announced that Tresiba and Ryzodeg 70 30 have gained the long awaited FDA approval for the treatment of diabetes mellitus in adults. Novo Nordisk intends to launch Tresiba in the U.S. during the first quarter of 2016.
Novo Nordisk's Tresiba & Ryzodeg Gain Entry into the U.S.
